NewLimit
San Francisco, United States · Biotechnology · 51 employees
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and
Funding history
- Funding Round — $435.0M — Jun 2026
- Funding Round — $45.0M — Oct 2025
- Venture - Series Unknown — $129.8M — May 2025
- Series B — $130.0M — May 2025
- Venture - Series Unknown — $72.2M — Jan 2025
Recent signals
- Jun 02, 2026: Raised $435.0M in Funding Round
- Oct 21, 2025: Raised $45.0M in Funding Round
- May 15, 2025: Raised $129.8M in Venture - Series Unknown
- May 07, 2025: Raised $130.0M in Series B
- Jan 07, 2025: Raised $72.2M in Venture - Series Unknown
- May 17, 2023: Raised $72.2M in Venture - Series Unknown
- May 16, 2023: Raised $40.0M in Funding Round
See plans & pricing → Track NewLimit’s funding, hiring, and signals — with verified contacts — on Fundz.